{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-110952","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2025-08-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.212655+00:00","generated_at":"2026-05-17T10:38:08.037975+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Invivyd closes $57.5M public offering; net proceeds ~$53.5M for pipeline development","bullets":["Raised ~$57.5M gross ($53.5M net) via 89.2M shares at $0.52/sh and 21.3M pre-funded warrants at $0.5199.","Underwriters' full option exercised; offering led by RA Capital Management and Janus Henderson.","Proceeds to fund VYD2311 clinical program, RSV/measles R&D, and Long COVID studies (SPEAR Study Group).","Dilution: total shares outstanding increases by ~110.6M (including pre-funded warrants exercisable)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-110952","json":"https://secwatch.observer/filing/0000950170-25-110952.json","markdown":"https://secwatch.observer/filing/0000950170-25-110952.md","text":"https://secwatch.observer/filing/0000950170-25-110952.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000095017025110952/0000950170-25-110952-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000095017025110952/ivvd-20250820.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T10:38:08.037975+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}